Recruitment

Recruitment Status
Unknown status

Inclusion Criteria

Patient undergoing frozen embryo transfer
Patient undergoing frozen embryo transfer

Exclusion Criteria

Body mass index (BMI) > 38 kg/m2
Patient not able to communicate adequately with the investigators and to comply with the requirements of the entire study.
Early follicular phase (day 2-4) serum follicle stimulating hormone (FSH) level > 20 mIU/ml.
...
Body mass index (BMI) > 38 kg/m2
Patient not able to communicate adequately with the investigators and to comply with the requirements of the entire study.
Early follicular phase (day 2-4) serum follicle stimulating hormone (FSH) level > 20 mIU/ml.
Contraindication for the use of nifedipine, Estrogen and Progesterone suppositories.
Abnormal uterine cavity as evidenced by sonohysterogram or hysterosalpingography
Any ovarian or abdominal abnormality that may interfere with adequate transvaginal sonography (TVS) evaluation.
Any contraindication to being pregnant and carrying a pregnancy to term.
Unwillingness to give written informed consent. Previous entry into this study or simultaneous participation in another clinical trial.
Patient treating with other drugs that interact with cytochrome P450 activity: azole antifungals, cimetidine, cyclosporine, erythromycin, quinidine, terfenadine, warfarin, benzodiazepines, flecainide, imipramine, propafenone and theophylline.
Irregular heart beat or already being treated with another medication for high blood pressure.
Administration of any investigational drugs within three months prior to study enrollment.

Summary

Conditions
Embryo Implantation
Type
Interventional
Phase
Phase 2
Design
  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Masking: Double (Participant, Care Provider)
  • Primary Purpose: Treatment

Participation Requirements

Age
Between 18 years and 45 years
Gender
Only females

Inclusion Criteria

Patient undergoing frozen embryo transfer
Patient undergoing frozen embryo transfer

Exclusion Criteria

Body mass index (BMI) > 38 kg/m2
Patient not able to communicate adequately with the investigators and to comply with the requirements of the entire study.
Early follicular phase (day 2-4) serum follicle stimulating hormone (FSH) level > 20 mIU/ml.
...
Body mass index (BMI) > 38 kg/m2
Patient not able to communicate adequately with the investigators and to comply with the requirements of the entire study.
Early follicular phase (day 2-4) serum follicle stimulating hormone (FSH) level > 20 mIU/ml.
Contraindication for the use of nifedipine, Estrogen and Progesterone suppositories.
Abnormal uterine cavity as evidenced by sonohysterogram or hysterosalpingography
Any ovarian or abdominal abnormality that may interfere with adequate transvaginal sonography (TVS) evaluation.
Any contraindication to being pregnant and carrying a pregnancy to term.
Unwillingness to give written informed consent. Previous entry into this study or simultaneous participation in another clinical trial.
Patient treating with other drugs that interact with cytochrome P450 activity: azole antifungals, cimetidine, cyclosporine, erythromycin, quinidine, terfenadine, warfarin, benzodiazepines, flecainide, imipramine, propafenone and theophylline.
Irregular heart beat or already being treated with another medication for high blood pressure.
Administration of any investigational drugs within three months prior to study enrollment.

Tracking Information

NCT #
NCT02072291
Collaborators
Not Provided
Investigators
  • Principal Investigator: Assaf Ben-Meir, MD Hadassah Medical Center
  • Assaf Ben-Meir, MD Hadassah Medical Center
About Us
Innovation
Privacy
Terms
Copyright
Get Well Soon © Copyright 2023